CLL

Allogeneic Hematopoietic Stem Cell Transplant Effective for Patients with CLL Previously Treated with Novel Agents

September 3rd 2020, 9:00pm

Allogeneic hematopoietic stem cell transplant’s role in the chronic lymphocytic leukemia has changed due to new novel agents, but research shows its still effective despite novel agent exposure.

Copiktra Plus Chemotherapy Needs Further Study of Toxicities in Patients With CLL

September 2nd 2020, 6:04pm

Article

An early phase 1b/2 study of Copiktra in combination of standard of care shows how the treatment is active for patients with chronic lymphocytic leukemia but further study is needed to ensure it is an effective and safe alternative to standard of care.

Arzerra Will Be Available at No Cost to Patients with Chronic Lymphocytic Leukemia in US

August 29th 2020, 2:00pm

Article

Arzerra will be available at no cost to patients via an oncology patient access program which will be facilitated through Patient Access Novartis Oncology.

Understanding Chronic Lymphocytic Leukemia

August 25th 2020, 6:00pm

Video

CURE speaks with Dr. Susan O'Brien, on behalf of the Leukemia and Lymphoma Society.

'Alexa For Health Care': New Virtual Assistant Helps Patients with Cancer at Home

August 8th 2020, 1:00am

Article

WellBe, a new voice-enabled virtual assistant, can remind patients with cancer to take their medication and keep them on track from the comfort of their own home.

Venclexta-Gazyva Combo Creates More Long-Term Treatment Options for Patients with CLL

August 5th 2020, 11:23pm

Article

Dr. Othman Al-Sawaf discusses the encouraging long-term data that makes the Venclexta-Gazyva combination a viable treatment option for patients with CLL.

Follow-Up Data Confirm Support for Use of Calquence in Patients with Relapsed/Refractory CLL, Expert Says

August 5th 2020, 7:00pm

Article

“Final results from ASCEND confirm the findings of the interim analysis and support the favorable efficacy and safety of (Calquence) versus standard-of-care regimens in relapsed or refractory CLL,” said Dr. Paolo Ghia.

Brukinsa May Cause Fewer Side Effects Than Other BTK Inhibitors for Patients with B-Cell Malignancies

August 5th 2020, 1:21am

Article

A clinical trial of Brukinsa (zanubrutinib) is open to patients with B-cell blood cancers and will determine whether the side effects re-emerge with Brukinsa.

CURE's Clinical Trial Corner: July 2020

July 30th 2020, 10:00pm

Article

A list of the recent trial initiations that occurred within the cancer space in July.

3 Drug Treatment Puts Some Patients With CLL On the Road to Remission

July 21st 2020, 10:00pm

Article

A three-drug treatment sparked complete responses in more than half of patients with high-risk chronic lymphocytic leukemia, who also tolerated the regimen well.